198 related articles for article (PubMed ID: 19238019)
1. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A
J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019
[TBL] [Abstract][Full Text] [Related]
2. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Shen J; Zhu Z
Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
[TBL] [Abstract][Full Text] [Related]
3. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
[TBL] [Abstract][Full Text] [Related]
4. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
5. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
6. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
[TBL] [Abstract][Full Text] [Related]
7. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
8. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
[TBL] [Abstract][Full Text] [Related]
10. Catumaxomab: a bispecific trifunctional antibody.
Sebastian M; Kuemmel A; Schmidt M; Schmittel A
Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225
[TBL] [Abstract][Full Text] [Related]
11. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R
Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039
[TBL] [Abstract][Full Text] [Related]
12. Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
Bokemeyer C
Expert Opin Biol Ther; 2010 Aug; 10(8):1259-69. PubMed ID: 20624115
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
Hirschhaeuser F; Walenta S; Mueller-Klieser W
Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
[TBL] [Abstract][Full Text] [Related]
14. Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.
Borlak J; Länger F; Spanel R; Schöndorfer G; Dittrich C
Oncotarget; 2016 May; 7(19):28059-74. PubMed ID: 27058902
[TBL] [Abstract][Full Text] [Related]
15. Catumaxomab: in malignant ascites.
Frampton JE
Drugs; 2012 Jul; 72(10):1399-410. PubMed ID: 22676343
[TBL] [Abstract][Full Text] [Related]
16. First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer.
Papanikolaou G; Fotopoulou C; Braicu I; Chekerov R; Schmidt SC; Pietzner K; Sehouli J
Anticancer Res; 2011 Aug; 31(8):2603-8. PubMed ID: 21778311
[TBL] [Abstract][Full Text] [Related]
17. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).
Seimetz D
J Cancer; 2011; 2():309-16. PubMed ID: 21716847
[TBL] [Abstract][Full Text] [Related]
18. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of pleural effusion caused by lung carcinoma with circular intrapleural hyperthermic perfusion and its mechanism].
Kang M; Zhou L; Lin P
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1176-9. PubMed ID: 11769704
[TBL] [Abstract][Full Text] [Related]
20. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Ruf P; Bauer HW; Schoberth A; Kellermann C; Lindhofer H
Cancer Immunol Immunother; 2021 Sep; 70(9):2727-2735. PubMed ID: 33837852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
